Status:

COMPLETED

Bioenergetics and Metabolism in Pediatric Populations

Lead Sponsor:

Arkansas Children's Hospital Research Institute

Collaborating Sponsors:

National Institutes of Health (NIH)

National Institute of General Medical Sciences (NIGMS)

Conditions:

Obesity

Type 2 Diabetes Mellitus

Eligibility:

All Genders

5-17 years

Brief Summary

The investigators want to learn more about obesity, the development of insulin resistance, and Type 2 Diabetes in children. The investigators will do this through collecting information about children...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Age 5-9 years and Tanner stage as reported by parent no greater than stage 1 OR Age 5 years - 17 years 5 months, diagnosed with type 2 diabetes mellitus or insulin resistance
  • Either healthy lean (BMI≥ 5th percentile and \<85th percentile for age/sex) or obese (BMI ≥ 95th percentile for age/sex)
  • For those with BMI≥ 95th percentile for age/sex, parental verbal confirmation will be obtained that the child had a history of BMI≥ 95th percentile for age/sex for at least six months prior to study enrollment
  • Exclusion criteria:
  • Genetic or physical conditions impacting mobility over past year as determined by the Principal Investigator (PI)
  • Having known chronic illnesses/disorders that may independently affect study outcome measures: type 1 diabetes mellitus, neurologic (e.g. epilepsy), developmental (developmental delay, autism spectrum disorder), endocrine (thyroid, Cushing's), hepatic, autoimmune, cardiac and renal disorders. Also, chronic lung disorders except well controlled asthma that does not require permanent use of inhaled/oral steroids
  • Taking any of the following medications that can affect study outcome: antipsychotics, thyroid hormone replacement therapy, inhaled/oral steroids, insulin, anabolic drugs (growth hormone replacement therapy and oxandrolone) and stimulants
  • BMI\<5th percentile for age/sex (classified as underweight based on Centers for Disease Control and Prevention growth charts)
  • Subjects determined ineligible by the PI.

Exclusion

    Key Trial Info

    Start Date :

    October 18 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2024

    Estimated Enrollment :

    79 Patients enrolled

    Trial Details

    Trial ID

    NCT03323294

    Start Date

    October 18 2017

    End Date

    June 30 2024

    Last Update

    February 13 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Arkansas Children's Hospital

    Little Rock, Arkansas, United States, 72202